Inflammatory Bowel Disease Testing Services

Inflammatory Bowel Disease (IBD) is a chronic disease impacting nearly 1.2 million Americans.1 Developments in treatment, such as biologics, have greatly improved quality of life for patients and advancements in laboratory testing are helping to support diagnosis and optimize therapy. LabCorp offers leading expertise and comprehensive testing services to support physicians in the management of IBD patients.

For a detailed look at how LabCorp's IBD test offerings support complete care decisions, see our IBD Test Offerings Matrix in the Related Documents section below. 

IBD Treatment Monitoring

Patient response to IBD treatments may be highly variable but new Therapeutic Drug Monitoring (TDM) assays can help optimize therapy using a personalized, patient-specific approach.

Monitoring Biologics

Biologics monitoring assays measure both drug concentration and anti-drug antibodies to support improved clinical outcomes and characterize those patients who may have diminished response to therapy.2, 3, 4, 5

  • All biologics have variable pharmacokinetics and the potential to induce an antibody-mediated immune response 6,7
  • TDM helps optimize dosing and frequency of treatment 2,7,8
  • TDM assists in preventing and managing loss of response due to immunogenicity9,10
  • TDM has been shown to be cost-effective and may direct more appropriate care.7

Biologic Drug Name

LabCorp Test

LabCorp Test No

Infliximab

Remicade®
Inflectra®

Infliximab Concentration and Anti-Infliximab Antibody

503870

Adalimumab

Humira®

Adalimumab Concentration and Anti-Adalimumab Antibody

503890

Vedolizumab

Entyvio®

Vedolizumab Concentration and Anti-Vedolizumab Antibody

504567

Golimumab

Simponi®

Golimumab and Anti-Golimumab Antibody

504563

 

Patient-specific clinical context must be taken into account when evaluating drug and anti-drug antibody. Serial measurements over time may be helpful. NOTE: These target ranges were those used in landmark studies and do not necessarily transplant into general recommendations for individual patients. Trough collections are recommended in most cases.

Monitoring Immunomodulators

Monitoring drug levels for Immunomodulators supports dosing decisions, assessing patient compliance, and determining effectiveness of treatment.

  • Utilize during treatment to help reach and maintain therapeutic goal11
  • Assists with evaluating unresponsive patients11
  • Thiopurine drugs monitoring helps avoid potential toxicity in responsive patients11
  • Approximately 30% ñ 40% of RA patients do not adequately respond to methotrexate treatment12

Drug Name

LabCorp Test

LabCorp Test No

Purinethol®
Azasan®
Imuran®
Tabloid®

Thiopurine Metabolites

503800

Rasuvo®
Rheumatrex®
DosePack®
Otrexup®
Trexall®

Methotrexate Polyglutamates

504104

TPMT genetic and TPMT activity testing is additionally available to assess dosing prior to Thiopurine treatment, as well as to identify patients who may be at risk for drug toxicity.

IBD Diagnosis

A combination of clinical findings, endoscopic, histopathologic, radiologic, and laboratory testing is used to establish the diagnosis of IBD.

Diagnostic challenges arise when clinical presentation is indolent, invasive procedures are not obtainable, or results are inconclusive. Novel serological markers for IBD offer improved sensitivity and specificity to aid in differential diagnosis and provide valuable prognostic information about disease behavior.

 

The LabCorp Difference

• Comprehensive laboratory services for the gastroenterology specialist
• Broad network of managed care health plans
• Flexible connectivity options for test ordering and reporting
• Patient service centers available nationwide
• Local account representation